Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:ASNDNASDAQ:BBIONYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.26+0.6%$29.84$22.90▼$36.45$4.80B0.471.73 million shs1.48 million shsASNDAscendis Pharma A/S$175.78-0.6%$165.32$111.09▼$183.00$10.81B0.37496,012 shs399,955 shsBBIOBridgeBio Pharma$42.17+1.1%$36.25$21.62▼$42.20$7.92B1.112.52 million shs2.59 million shsOGNOrganon & Co.$9.82+0.7%$9.86$8.01▼$23.10$2.53B0.593.46 million shs3.28 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+0.58%-0.54%-0.31%-13.64%+17.27%ASNDAscendis Pharma A/S-0.63%-1.09%+8.51%+9.15%+37.49%BBIOBridgeBio Pharma+1.05%+2.50%+26.48%+14.78%+54.13%OGNOrganon & Co.+0.56%-3.75%+13.00%-33.38%-52.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.7703 of 5 stars4.41.00.04.23.32.51.9ASNDAscendis Pharma A/S3.2457 of 5 stars4.53.00.00.01.51.70.6BBIOBridgeBio Pharma4.5528 of 5 stars4.52.00.03.92.03.30.6OGNOrganon & Co.4.696 of 5 stars3.32.01.73.71.73.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$40.0036.71% UpsideASNDAscendis Pharma A/S 3.00Buy$220.6725.54% UpsideBBIOBridgeBio Pharma 2.92Moderate Buy$56.6734.38% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0083.30% UpsideCurrent Analyst Ratings BreakdownLatest ASND, BBIO, ALKS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/17/2025BBIOBridgeBio PharmaWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$49.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/9/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$53.00 ➝ $56.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.10$2.67 per share10.97$9.05 per share3.23ASNDAscendis Pharma A/S$393.54M27.30N/AN/A($1.88) per share-93.50BBIOBridgeBio Pharma$221.90M36.08N/AN/A($7.71) per share-5.47OGNOrganon & Co.$6.40B0.40$4.96 per share1.98$1.83 per share5.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0914.0021.361.8023.30%27.52%17.98%7/23/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$6.28N/A732.42N/A-93.22%N/A-33.29%9/2/2025 (Estimated)BBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)OGNOrganon & Co.$864M$2.883.412.631.0211.92%227.43%7.34%8/5/2025 (Estimated)Latest ASND, BBIO, ALKS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.81%N/A2.78%N/ALatest ASND, BBIO, ALKS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.332.92ASNDAscendis Pharma A/SN/A1.040.71BBIOBridgeBio PharmaN/A4.574.54OGNOrganon & Co.16.491.671.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%ASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%ASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma18.20%OGNOrganon & Co.1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableOGNOrganon & Co.4,000259.96 million256.32 millionNot OptionableASND, BBIO, ALKS, and OGN HeadlinesRecent News About These CompaniesOrganon & Co. (NYSE:OGN) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 24 at 2:11 AM | americanbankingnews.comOGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)June 23 at 10:51 PM | morningstar.comOGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)June 23 at 10:51 PM | morningstar.comContact The Gross Law Firm by July 22, 2025 Deadline to Join Class Action Against Organon & Co. (OGN)June 23 at 4:00 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGNJune 23 at 11:06 AM | globenewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGNJune 23 at 9:00 AM | prnewswire.comORGANON & CO. (NYSE: OGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Organon & Co. Investors of Upcoming DeadlineJune 23 at 8:30 AM | globenewswire.comROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Organon & Co. ...June 22 at 2:20 PM | gurufocus.comROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGNJune 22 at 1:19 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon ...June 22 at 11:32 AM | gurufocus.comOGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class ...June 22 at 10:00 AM | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGNJune 22 at 10:00 AM | prnewswire.comOGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action -- Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)June 22 at 9:33 AM | globenewswire.comOGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud LawsuitJune 21 at 5:49 PM | gurufocus.comORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 20, 2025 | prnewswire.comOGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud LawsuitJune 20, 2025 | prnewswire.comOGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 20, 2025 | globenewswire.comDeadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJune 20, 2025 | globenewswire.comFaruqi & Faruqi Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGNJune 20, 2025 | prnewswire.comOGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)June 20, 2025 | globenewswire.comCantor Fitzgerald Investment Advisors L.P. Decreases Position in Organon & Co. (NYSE:OGN)June 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeChina Market Movers: MCHI, PDD, BIDU Show Bullish TrendsBy Gabriel Osorio-Mazilli | June 16, 2025View China Market Movers: MCHI, PDD, BIDU Show Bullish TrendsTariff Talks Advance, What Taiwan Semiconductor Can DeliverBy Gabriel Osorio-Mazilli | June 16, 2025View Tariff Talks Advance, What Taiwan Semiconductor Can DeliverASND, BBIO, ALKS, and OGN Company DescriptionsAlkermes NASDAQ:ALKS$29.26 +0.17 (+0.58%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$29.27 +0.01 (+0.03%) As of 06/23/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Ascendis Pharma A/S NASDAQ:ASND$175.78 -1.12 (-0.63%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$175.79 +0.01 (+0.01%) As of 06/23/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$42.17 +0.44 (+1.05%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$41.22 -0.95 (-2.25%) As of 06/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Organon & Co. NYSE:OGN$9.82 +0.07 (+0.72%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$9.83 +0.01 (+0.10%) As of 06/23/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
